Fingrut, MD, assistant professor of stem cell transplantation and cellular therapy at The University of Texas MD Anderson Cancer Center. Stem cell donations can be done in different ways ...

There are two basic types of lung cancer: small cell (SCLC), the most aggressive type of lung cancer, and non-small cell (NSCLC), the most common type (which includes several subtypes). Rather than ...

More information: Braelyn Binkowski et al, Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples, Science Advances (2025 ...

S, Principal Investigator at A*STAR SRL are co-authors of the study. While the current study focuses on basal cell carcinoma (BCC), researchers believe the technology could also be adapted to ...

Immunotherapies treat cancer by speeding up tumor cell death, and treat autoimmune disorders—in which the body's immune system attacks its own cells—by tamping down such reactions.

That worked, for a while. "It kept it out for 10 years," Cannella said, before the cancer returned in 2015. CAR T cell therapy advanced from laboratory findings in the 1980s to successful clinical ...

Once non-small-cell lung cancer (NSCLC) spreads far and wide, treating it is kind of a balancing act. A cure isn't likely, but you can slow it down. So you aim to relieve your symptoms and improve ...

In our recent publication in Gut,1 we showed that preoperative gut microbiota was causally linked to the development of anastomotic leak (AL) after colorectal cancer (CRC ... Most importantly, these ...

in the treatment of basal cell carcinoma (BCC), with positive data outcomes. The study included patients who had relapsed after standard therapies and had no other treatment options. Among them, three ...

Harnessing immunosuppressive tumour microenvironment for a durable response in solid tumours While CAR T-cell therapy has revolutionised blood cancer treatment, its application to solid tumours has ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma. The FDA has granted clearance to initiate a global ...